Chelsea Therapeutics International (NASDAQ:CHTP) is one of today's worst performing penny stocks, down 7.2% to $0.75 on 1.8x average daily volume. Chelsea Therapeutics International has traded 2.6 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-7.4% to the Dow's -0.5%) and underperformed the S&P 500 (-7.4% to the S&P's -0.5%) during today's trading.
In the past 52 weeks, Chelsea Therapeutics International share prices have been bracketed by a low of $0.70 and a high of $5.40 and are now at $0.75, 7% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.8% while the 200-day MA has slid 2.5%.
Chelsea Therapeutics International has overhead space with shares priced $0.75, or 78.6% below the average consensus analyst price target of $3.50. Chelsea Therapeutics International shares should first meet resistance at the 50-day moving average (MA) of $1.35 and find additional resistance at the 200-day MA of $1.56.
Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.